Skip to content

Vascular Closure

Rapid hemostasis for arterial and venous access sites
Our portfolio of vascular closure products provides rapid hemostasis for interventional and electrophysiology procedures to help clinicians reduce the risk of complications, improve patient satisfaction, and enable same day discharge.

Haemonetics Vascular Closure VASCADE
Optimizing Vascular Access Management
• Enables same day discharge following AF ablation with VASCADE MVP® Venous Vascular Closure System (VVCS)
• Reduces the risk of access site complications with VASCADE® Vascular Closure System (VCS), as demonstrated in the RESPECT Clinical Trial1
• Offers an outcomes-based risk-sharing VASCADE Performance Guarantee program – Sharing Risk by Sharing Costs
1. Hermiller JB, et.al. A Prospective, Randomized, Pivotal Trial of a Novel Extravascular Collagen-Based Closure Device Compared to Manual Compression in Diagnostic and Interventional Patients Journal of Invasive Cardiology 2015;27(3):129-136.

2. IFUs and / or SSEDs of commercially available leading brands (VASCADE®, AngioSeal®, Mynx®, Perclose™, Starclose™, Exoseal®).

3. IFUs of commercially available venous vascular closure devices: VASCADE MVP®, MYNXGRIP®, Perclose ProGlide™ and Perclose ProStyle™. As of 1 October, 2022; Catheter-based cardiac ablations requiring two or more venous access sites within the same limb.

LIT 5832 REV AA

Connect with Vascular Closure


Haemonetics Vascular Closure LinkedIn    Haemonetics Vascular Closure Twitter